The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index - Which is the best predictor of prostate cancer after a negative biopsy?

Journal of Urology

Volumn 192, Issue 1, 2014, Pages 60-66

  Porpiglia, Francesco ^a   Russo, Filippo ^c   Manfredi, Matteo ^a   Mele, Fabrizio ^a   Fiori, Cristian ^a   Bollito, Enrico ^b   Papotti, Mauro ^b   Molineris, Ivan ^b   Passera, Roberto ^b   Regge, Daniele ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

biopsy; human; magnetic resonance imaging; prostate cancer antigen 3; prostatic neoplasms

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATE VOLUME; RECEIVER OPERATING CHARACTERISTIC; REPEAT PROCEDURE; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; UROLOGIST; COMPARATIVE STUDY; LABORATORY DIAGNOSIS; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; URINE;

ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; FALSE NEGATIVE REACTIONS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84902548325     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.01.030     Document Type: Article

References (30)

1. A. Heidenreich, P.J. Bastian, and J. Bellmunt et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013 Eur Urol 65 2014 124
2. J.S. Jones, A. Patel, and L. Schoenfield et al. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy J Urol 175 2006 485
3. B. Djavan, V. Ravery, and A. Zlotta et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 2001 1679
4. S. Loeb, A. Vellekoop, and H.U. Ahmed et al. Systematic review of complications of prostate biopsy Eur Urol 64 2013 876
5. M.C. Gittelman, B. Hertzman, and J. Bailen et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study J Urol 190 2013 64
6. M. Lazzeri, A. Briganti, and V. Scattoni et al. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy J Urol 188 2012 1137
7. C. Stephan, K. Jung, and A. Semjonow et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer Clin Chem 59 2013 280
8. V. Scattoni, M. Lazzeri, and G. Lughezzani et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy J Urol 190 2013 496
9. S. Perdonà, D. Bruzzese, and M. Ferro et al. Prostate Health Index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy Prostate 73 2013 227
10. A. Sciarra, J. Barentsz, and A. Bjartell et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer Eur Urol 59 2011 962
11. P. Puech, E. Potiron, and L. Lemaitre et al. Dynamic contrast-enhanced MRI evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens Urology 74 2009 1094
12. C.M. Hoeks, J.O. Barentsz, and T. Hambrock et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging Radiology 261 2011 46
13. A. Tanimoto, J. Nakashima, and H. Kohno et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging J Magn Reson Imaging 25 2007 146
14. J.O. Barentsz, J. Richenberg, and R. Clements et al. ESUR prostate MR guidelines 2012 Eur Radiol 22 2012 746
15. N. Arumainayagam, H.U. Ahmed, and C.M. Moore et al. Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard Radiology 268 2013 761
16. A. Semjonow, T. Kopke, and E. Eltze et al. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum Clin Biochem 43 2011 926
17. L. Dickinson, H.U. Ahmed, and C. Allen et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting Eur Urol 59 2011 477
18. J.J. Futterer MR imaging in local staging of prostate cancer Eur J Radiol 63 2007 328
19. F. Rodríguez-Covarrubias, A. González-Ramírez, and B. Aguilar-Davidov et al. Extended sampling at first biopsy improves cancer detection rate: results of a prospective, randomized trial comparing 12 versus 18-core prostate biopsy J Urol 185 2011 2132
20. A. De Matteis, E. Bollito, and A.B. Galosi et al. Prostate biopsy: characteristics of the histological sample Arch Ital Urol Androl 77 2005 28
21. A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565
22. X. Filella, L. Foj, and M. Milà et al. PCA3 in the detection and management of early prostate cancer Tumour Biol 34 2013 1337
23. F.H. Jansen, R.H. van Schaik, and J. Kurstjens et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921
24. S. Cirillo, M. Petracchini, and P. Della Monica et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours Clin Radiol 63 2008 871
25. A. Sciarra, V. Panebianco, and S. Cattarino et al. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy BJU Int 110 2012 1661
26. P. Puech, O. Rouvière, and R. Renard-Penna et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy-prospective multicenter study Radiology 268 2013 461
27. P.A. Pinto, P.H. Chung, and A.R. Rastinehad et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging J Urol 186 2011 1281
28. C.M. Moore, N.L. Robertson, and N. Arsanious et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review Eur Urol 63 2013 125
29. M.M. Siddiqui, S. Rais-Bahrami, and H. Truong et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy Eur Urol 64 2013 713
30. M.C. Roethke, T.H. Kuru, and S. Schultze et al. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla Eur Radiol 24 2014 344